There appears to be a rise in COVID-19 illnesses, driven by Omicron subvariants, which may be better able to evade immunity from vaccines and previous infections and lower public health measures by the public such as masking and social distancing.

AstraZeneca moved to bolster the company’s COVID-19 portfolio of antibodies on May 17 with a $157 million licensing deal for experimental therapies developed by newly launched biotech RQ Bio.

Although 2020 was a tough year for the biopharma industry — and most other industries as well — it appeared to rebound significantly in mid-2021. However, biotech stocks are generally getting hammered during 2022, although to be fair, the entire stock market is down.

Despite the loss of the company’s COVID-19 antibody REGEN-COV earlier in 2022, Regeneron posted a positive first quarter driven primarily by sales of Dupixent and Eylea.

Two new sublineages of the Omicron coronavirus variant can dodge antibodies from earlier infection well enough to trigger a new wave, but are far less able to thrive in the blood of people vaccinated against COVID-19, South African scientists found.

Eli Lilly had a lucrative first-quarter 2022, with revenue growth rising 15 percent driven by sales of the company’s diabetes drug Trulicity and its COVID-19 antibodies.

Unvaccinated people infected with the Omicron variant are unlikely to develop immune responses that will protect them against other variants of the coronavirus, a new study suggests. Additionally, the average number of global deaths from COVID-19 were 6 percent higher on weekends compared to weekdays throughout the pandemic, according to statistics reported to the World Health Organization between March 2020 and March 2022.

The U.S. Food and Drug Administration extended by three months the regulator agency’s review of Regeneron Pharmaceuticals Inc.’s application for full approval of the COVID-19 antibody therapy combination of casirivimab and imdevimab, the U.S. drugmaker said on April 14.

The U.S. health regulator said on March 25 the current authorized dose of GlaxoSmithKline and Vir Biotechnology’s COVID-19 antibody therapy is unlikely to be effective against the Omicron BA.2 variant.

AstraZeneca said on March 21 the company’s antibody-based cocktail to prevent and treat COVID-19 retained neutralizing activity against Omicron coronavirus variants, including the highly contagious BA.2 sub-variant, in an independent lab study.